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INtrODUCtION
In the early literature, one of the most striking 
symptoms reported for the vitamin C deficiency 
disease scurvy was a marked susceptibility to 
infections, particularly pneumonia (reviewed in 
[1]). Autopsy findings from the 1920s indicated 
that pneumonia was one of the most frequent 
complications of scurvy and was the prevailing 
cause of death. Infantile scurvy was also observed 
to predispose children to infections, particularly 
of the respiratory tract. According to Hemilä 
[1], these findings supported observations of the 
disappearance of a pneumonia epidemic in Sudan 
when antiscorbutic treatment was given to the 
numerous cases of scurvy that occurred at the same 
time. Conversely, there have also been reports of 
scurvy following infectious epidemics, suggesting 
that infections can severely deplete vitamin C 
levels in the body [1]. Case reports indicate that 
children have developed scurvy symptoms after, 
or concurrently with, respiratory infections [2,3]. 
The authors stated that “possibly the increased 
metabolic needs associated with this infection 
unmasked a subclinical vitamin  C deficiency” 
[2] and that “scurvy occurred as a result of their 
increased requirement of vitamin C due to stress 
of illness combined with poor dietary intake. It 
is therefore recommended that during illness one 
should be careful about the intake of vitamin C, 
keeping in mind that acute illness rapidly depletes 
stores of ascorbic acid. Those already malnourished 
are more prone to this development” [3]. Similarly, 
others have reported scurvy symptoms following 
confirmed or suspected respiratory infection, 
stating that “sepsis of either digestive or pulmonary 
origin, leading to sustained metabolic demand, 
might have acted as a precipitating factor” [4,5].
The anecdotal and epidemiological observations 
of a connection between vitamin C status and 
infections have been supported by animal studies 
using vitamin C–requiring guinea pigs and 
mice deficient in L-gulono-γ-lactone oxidase 
(Gulo−/−), the rate-limiting enzyme in vitamin C 
synthesis. Identification of bacteria in the tissues 
of scorbutic guinea pigs in the early literature led 
to the erroneous hypothesis by some researchers 
that scurvy may in fact be an infectious disease 
[1]. Research has indicated an increased severity 
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of infections in scorbutic guinea pigs, with higher 
mortality observed in vitamin C–deficient animals 
infected with Pseudomonas aeruginosa compared 
with vitamin C–replete animals [6]. Vitamin C–
deficient Gulo knockout mice were three times as 
likely as vitamin C–replete mice to die following 
infection with Klebsiella pneumoniae [7]. The lungs 
appear to be particularly susceptible to deficiency 
with vitamin  C–deficient Gulo knockout mice 
exhibiting greater lung pathology following 
infection with influenza [8]. Conversely, infection 
of animals with P. aeruginosa and influenza A 
virus resulted in decreased vitamin C levels in 
tissues and fluids [6,9,10], possibly due to the 
inflammatory response and enhanced oxidative 
stress. Interestingly, infection by itself was found to 
decrease antioxidant capacity more than a vitamin 
C–deficient diet in guinea pigs, suggesting a high 
consumption of antioxidants during infection [6]. 
Although enhanced markers of oxidative stress 
have been observed in infected mice, there were 
no significant differences in the levels of the 
oxidation products in the vitamin  C–deficient 
and –replete mice indicating that vitamin C may 
be acting via mechanisms other than oxidant 
scavenging [7]. Overall, the animal studies support 
a two-way relationship between vitamin C and 
infection.
PNEUMONIa aND VItaMIN C
Pneumonia is an acute infection of the lungs that 
can be caused by a range of microorganisms, 
including those of bacterial, fungal, or viral 
origin [11]. These microorganisms reach the lower 
respiratory tract and, dependent on microbial 
virulence factors, the host’s immune defenses, 
and integrity of barriers, cause inflammation in 
the alveoli and consequently result in pneumonia. 
Diagnosis is usually determined through 
radiographic imaging, indicating shadowing of a 
lobe or segment of the lung, and the clinician’s 
clinical assessment, and empiric treatment is 
through prompt antimicrobial intervention. 
Symptoms include cough, fever, aches, sweating, 
and shivering, and some patients may present 
with pleuritic chest pain and confusion [12]. 
Lower respiratory infections, such as pneumonia, 
are a leading cause of morbidity and mortality 
worldwide. In 2016, lower respiratory infections 
caused nearly 2.4 million deaths worldwide, 
making lower respiratory infections the sixth 
leading cause of mortality for all ages and the 
leading cause of death among children younger 
than 5 years [13]. This equated to more than 335 
million episodes of lower respiratory infections 
and more than 65 million hospital admissions 
in 2016. Lower respiratory infection mortality is 
high in the elderly, and rates are increasing due to 
an increasing aging population, with the number 
of adults older than 70 years increasing by 50% 
between 2000 and 2016 [14].
Streptococcus pneumoniae is the leading cause of lower 
respiratory infection morbidity and mortality 
globally, contributing to more deaths than all 
other assessed etiologies combined [14]. Research 
has also indicated that increased pneumonia 
incidence is associated with higher deprivation and 
is particularly prevalent in developing countries 
where poverty is more prevalent [14,15].
Pneumonia has been reported as one of the most 
common complications and causes of mortality in 
individuals with scurvy, suggesting an important 
link between vitamin C status and lower respiratory 
infection [1]. This premise is supported by meta-
analyses of three interventional studies that 
indicated that prophylactic administration of at 
least 200 mg/d vitamin C decreased the incidence 
of pneumonia in the study populations [16–19]. 
Furthermore, analysis of the vitamin C status of 
patients with pneumonia and acute respiratory 
distress syndrome has indicated significantly 
lower vitamin C concentrations in patients when 
compared with healthy controls, and levels 
appeared to inversely correlate with the severity 
of the condition (Table 7.1) [20,21]. Up to 40% 
of patients with pneumonia exhibited outright 
vitamin C deficiency (i.e., plasma vitamin  C 
levels <11 µmol/L), and levels remained low for 
at least 4 weeks [22,23]. These studies indicate 
a higher utilization of, and potentially also a 
higher requirement for, vitamin C during lower 
respiratory tract infection.
An early report by Klenner indicated that 
administration of 2–4 g/d intravenous or 
intramuscular doses of vitamin C to patients 
with pneumonia decreased the symptoms of 
nausea, headache, temperature, and cyanosis [24]. 
Subsequent interventional studies have indicated 
that administration of oral or intravenous 
vitamin C decreased the severity of the respiratory 
symptoms, particularly in the most severely ill, and 
also decreased hospital length of stay in a dose-
dependent manner (Table 7.2) [22,23]. A  trend 
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toward decreased mortality was observed in the 
interventional study by Hunt et  al. [22], and a 
more recent case control study using a higher dose 
of 6 g/d intravenous vitamin C (in combination 
with thiamine and hydrocortisone) exhibited a 
significant (56%) decrease in mortality in patients 
with severe pneumonia [25]. Interestingly, Cathcart 
hypothesized that patients with severe respiratory 
infections and pneumonia had higher requirements 
for vitamin C based on the observation that they 
could tolerate more than 10 times the usual bowel 
tolerance doses of 4–15 g/24 hour [26]. Mochalkin 
assessed plasma vitamin C levels following 
intervention and observed that administration 
of 0.25–0.8 g/d vitamin C was insufficient to 
maintain the patients’ initial vitamin C status; 
however, administration of 0.5–1.6 g/d vitamin C 
was able to maintain the patients’ plasma vitamin C 
status for the duration of the study (30 days) 
[23]. However, these plasma concentrations were 
still inadequate (i.e., <50 µmol/L), suggesting a 
requirement of >1.6 g/d for saturating plasma 
status. Thus, patients with severe infections, such 
as pneumonia, have higher requirements for 
TABLE 7.1
Vitamin C status of patients with pneumonia
Study Type Cohort Vitamin C (µmol/L) References





Case control 28 Healthy participants
35 Lobular pneumonia
 7 Acute—did not survive
 15 Acute—survived













24 ± 5 (40%)a
19 ± 3 (37%)















NOtE: Data represent mean and standard error of the mean (SEM).
a Percentage of patients with vitamin C deficiency. Vitamin C status categories: saturating (>70 µmol/L), adequate 
(>50 µmol/L), hypovitaminosis C (<23 µmol/L), and deficient (<11 µmol/L).
TABLE 7.2
Vitamin C intervention in patients with pneumonia
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 39 Low dose










aBBrEVIatIONS: ↓ decrease; IV, intravenous.
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vitamin C, and doses of vitamin C that provide 
adequate to saturating plasma vitamin C status in 
these patients appear to have beneficial effects on 
patient outcomes.
SEPSIS aND VItaMIN C
Sepsis is a condition of life-threatening organ 
dysfunction caused by a dysregulated host response 
to infection [27]. Sepsis is characterized by profound 
dysregulation of the circulatory, metabolic, and 
immune systems, and it is the primary cause 
of death from infection. Patients who develop 
septic shock can have hospital mortality rates of 
up to 50%. Management of sepsis involves fluid 
resuscitation for hypoperfusion and vasopressor 
drug administration for those in shock [28]. Global 
estimates indicate nearly 32 million sepsis cases and 
more than 5 million deaths annually [29]. Although 
sepsis mortality rates have been decreasing, 
particularly in developed countries such as the 
United States and Australasia, the incidence of 
sepsis continues to increase, likely due to an aging 
population [30–34]. Despite huge research efforts 
toward an attempt to identify effective sepsis 
therapies, to date most of these have proven futile 
[35]. Furthermore, patients who survive sepsis 
can often have long-term physical disabilities, 
cognitive dysfunction, or psychological issues, 
such as anxiety, depression, and posttraumatic 
stress disorder, which significantly affect their 
quality of life [36].
Case control studies have consistently indicated 
significantly lower vitamin C status in critically 
ill patients, particularly those with sepsis (Table 
7.3). These critically ill patients have by far the 
lowest vitamin C status when compared with 
other common disease states [37,38]. Lower 
vitamin C status in these patients was associated 
with increased inflammation (C-reactive protein 
levels), increased severity of the illness (days 
in the intensive care unit [ICU]), and multiple 
organ failure [37,39,40]. Nearly 40% of patients 
with septic shock were deficient, and almost 
90% had hypovitaminosis C, despite receiving 
recommended enteral and parenteral intakes [39]. 
Administration of 1 g/d vitamin C to critically ill 
patients was found to be insufficient to raise the 
patients’ plasma vitamin C concentrations above 
the hypovitaminosis C cutoff, but 3 g/d resulted 
in saturating plasma status (i.e., ∼70 µmol/L) 
[41,42]. Recent pharmacokinetic data indicated 
that administration of 2 g/d vitamin C to 
critically ill patients, as either bolus or continuous 
infusions, resulted in plasma concentrations in 
the normal range, although hypovitaminosis C 
occurred in some patients following cessation of 
the intervention, suggesting sustained therapy 
may be required to prevent this from occurring 
[43]. Overall, these findings indicate that critically 
ill patients have vitamin C requirements that 
are approximately 10-fold higher than healthy 
individuals, whose plasma vitamin C typically 
saturates with intakes of 0.2 g/d [44].
TABLE 7.3
Vitamin C status of patients with sepsis
Study Type Cohort Vitamin C (µmol/L) References
Observational 24 Septic shock patients 15 ± 2 (38%a, 88%b) [39]
Interventional (baseline) 24 Severe sepsis patients 18 ± 2 [45]












Case control 34 Healthy controls




NOtE: Data represent mean and standard error of the mean (SEM) or median and interquartile range.
aBBrEVIatION: ICU, intensive care unit.
a Percentage of patients with vitamin C deficiency.
b Hypovitaminosis C. Vitamin C status categories: saturating (>70 µmol/L), adequate (>50 µmol/L), hypovitaminosis C (<23 µmol/L), and 
deficient (<11 µmol/L).
119VItaMIN C IN PNEUMONIa aND SEPSIS
Critically ill patients treated with ∼3 g/d intra-
venous vitamin C (in combination with various 
other antioxidant vitamins and minerals) have 
shown improved outcomes, including decreased 
organ failure, ICU and hospital length of stay, mor-
tality, inflammation, and infections/sepsis [42,48–
51]. However, with combination interventions, it is 
difficult to know which component(s) are contrib-
uting to the various outcomes, particularly since 
baseline concentrations of the various components 
are not typically assessed in the patients prior to 
intervention. In 2014, the first phase I study inves-
tigating intravenous vitamin C as monotherapy 
in patients with sepsis was published [45]. In this 
study, 24 patients with severe sepsis were treated 
with 0, 50, or 200 mg/kg body weight intrave-
nous vitamin C per day, which provided a dose-
dependent decrease in systemic organ failure and 
decreased pro-inflammatory (C-reactive protein 
and procalcitonin) and tissue damage (throm-
bomodulin) biomarkers (Table 7.4). Although 
the study was not powered to detect a decrease 
TABLE 7.4
Vitamin C intervention in patients with sepsis
Patients Intervention Outcomes References




0 or 6 g/d
Duration: until ICU 
discharge
↓ Vasopressor duration
↓ ICU length of stay
X Length of mechanical ventilation






0 or 100 mg/kg/d
Duration: 3 days
↓ Norepinephrine dose and duration






0, 50, or 200 mg/kg/d
Duration: 4 days
↓ Systemic organ failure
↓ C-reactive protein, procalcitonin, 
thrombomodulin levels
[45]





0 or 6 g/d
+ thiamine
+ hydrocortisone
Duration: as little as 1 dose 
or up to 4 days
X ICU or hospital mortality
X ICU or hospital length of stay
X Renal replacement therapy for AKI







0 or 6 g/d
+ thiamine
Duration: 1 day only
X 28-day or hospital mortality
X ICU or hospital length of stay
X Duration of mechanical ventilation









↓ Vasopressin and noradrenaline requirements
↓ Procalcitonin levels






0 or 6 g/d
+ thiamine
+ hydrocortisone
Duration: 4 days or until ICU 
discharge
↓ Vasopressor duration
↓ Systemic organ failure
↓ Procalcitonin levels
↓ Renal replacement therapy
X ICU length of stay
↓ Hospital mortality
[57]
aBBrEVIatIONS: ↓ decrease; AKI, acute kidney injury; IV, intravenous; X, no change.
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in mortality, fewer participants died in the treat-
ment arms. Subsequently, a randomized controlled 
trial carried out in 28 patients with septic shock 
treated with 100 mg/kg body weight intravenous 
vitamin C per day showed a significant decrease 
in vasopressor requirements (dose and duration of 
norepinephrine) and a dramatic (78%) decrease in 
28-day mortality [52]. No difference in ICU length 
of stay was observed. Another recent randomized 
study administering 6 g/d vitamin C or placebo to 
100 septic shock patients also showed decreased 
requirements for vasopressors and decreased 
length of ICU stay [53]. However, no differences 
in ICU mortality, duration of mechanical ventila-
tion, or renal replacement therapy were observed 
between the two groups.
Several recent studies have investigated the 
efficacy of administering a cocktail of vitamin C 
with thiamine (vitamin B1), with or without 
hydrocortisone (Table 7.4). A before-and-after 
study was carried out in which 47 patients with 
severe sepsis were treated with 6 g/d intravenous 
vitamin C, in combination with 0.4 g/d thiamine 
(vitamin B1) and hydrocortisone, and were 
compared with 47 retrospective controls, who 
also received hydrocortisone at the attending 
physicians’ discretion [57]. This study also 
showed decreased vasopressor requirements, 
as well as decreased systemic organ failure and 
requirement for renal replacement therapy. 
Furthermore, a dramatic (79%) decrease in 
hospital mortality was observed in the group who 
received the intervention. A smaller randomized 
study administering the same cocktail of 
vitamin C, thiamine, and hydrocortisone to 24 
cardiac surgery patients with septic shock showed 
decreased vasopressin and norepinephrine 
requirements and decreased procalcitonin levels 
in the treatment group, although no difference 
in sequential organ failure assessment (SOFA) 
scores was observed between the two groups [56]. 
A recent retrospective analysis of septic patients 
administered the same cocktail, however, showed 
no effect of treatment on any of the assessed 
outcomes (i.e., hospital and ICU mortality and 
length of stay, renal replacement therapy for 
acute kidney injury, or time to vasopressor 
independence). It should be noted that patients 
were included in the analysis if they received as 
little as one dose of the cocktail, and although 
a subgroup analysis of the 20 patients who did 
receive the full 4 days (or until discharge) also 
showed no significant outcome effects, these 
numbers would likely be too low to provide 
appropriate power. Another before-and-after 
study administering vitamin C and thiamine, 
but without hydrocortisone, to 229 septic shock 
patients found no effect on ICU or hospital 
mortality or length of stay when compared with 
915 retrospective controls [55]. However, the 
treatment was administered for only 1 day, and 
the treatment group also had significantly higher 
baseline morbidity than the control group [58]. 
Despite this, in patients with the most severe 
organ dysfunction, the treatment did decrease 
mortality. Thus, most of these small studies have 
indicated that intravenous doses of ∼6–7 g/d 
vitamin C administered for 3–4 days may 
improve the outcomes of patients with sepsis and 
septic shock, including a decreased requirement 
for vasopressors [59]. Currently, over a dozen 
registered randomized controlled trials are 
underway around the world to determine if these 
encouraging findings are reproducible.
aCUtE LUNG DYSFUNCtION
Acute respiratory infections and sepsis can result 
in the development of acute lung injury which, 
in its most severe form, is known as acute 
respiratory distress syndrome [60]. During acute 
lung injury, bronchoalveolar barrier function is 
compromised, resulting in abnormal capillary 
permeability and pulmonary edema [61]. Sepsis-
induced acute lung injury is also associated 
with diminished expression and function of 
tight junction proteins in lung epithelium [62]. 
Furthermore, the iron pumps and channels that 
normally function to maintain continuous fluid 
clearance by the lungs can be affected early 
during sepsis [63]. In a murine model of sepsis-
induced acute lung injury, Fisher et al. reported 
that concurrent administration of 200 mg/kg 
vitamin C to mice attenuated the resultant lung 
dysfunction [62]. The authors reported decreased 
lung water and alveolar epithelial permeability 
and increased alveolar fluid clearance in the 
animals that received vitamin C. Furthermore, 
increased expression of iron pumps and channels 
and increased expression of tight junction and 
cytoskeletal connector proteins were observed 
over and above both sepsis-induced and control 
levels, suggesting enhanced gene transcription 
in the presence of vitamin C (Figure 7.1). Other 
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researchers have reported synergistic interactions 
between vitamin C and hydrocortisone in 
at tenuat ing l ipopolysacchar ide-induced 
hyperpermeability of human lung microvascular 
endothelial cells [64]. The combination was 
found to normalize the expression and activation 
of proteins associated with actin stress fibers, 
which play an important role in the formation 
and maintenance of cell-cell adhesion, including 
tight junctions. Recently, case reports have 
been published that demonstrate dramatic lung 
clearance in septic patients with acute respiratory 
distress syndrome of bacterial and viral origins 
following treatment with intravenous vitamin C 
[65,66]. Vitamin C was administered to the 
patients at a dose of 200 mg/kg/d, and within 1–2 
days there was observable clearance of the lung 
infiltrate upon chest x-ray (Figure 7.2). Similar 
lung clearance has been reported for vitamin C 
combination therapy in cases of noninfectious 
and aspiration-induced acute respiratory distress 
syndrome [67,68].
Effect of vitamin C administration
on septic lung dysfunction
↓ Excess lung water
↑ Alveolar fluid clearance
↑ Aqp5, ENaC, Na+–K+–ATPase, CFTR
↓ Alveolar epithelial permeability 
↑ Barrier function (↑ claudin-18,





















Figure 7.1. Effect of vitamin C administration on sepsis-induced acute lung injury in a mouse model. Vitamin C 
administration significantly increased expression of the key pumps and channels involved in alveolar fluid transport, 
including aquaporin 5 (Aqp5), cystic fibrosis transmembrane conductance regulator (CFTR), epithelial sodium channel 
(ENaC), and sodium-potassium-ATPase (Na+-K+-ATPase). Vitamin C administration also significantly increased expression 
of the tight junction proteins claudin-18 and occludin, as well as the cytoskeletal connector protein zona occludens-1. 
(↓ decreased, ↑ increased.) (The diagram is courtesy of R. Natarajan [personal communication], and the text box is a 
summary of findings from Fisher, B. J. et al. 2012. Am. J. Physiol. Lung Cell Mol. Physiol. 303, L20–L32.)
Day 3: before IVC Day 5: after IVC
Figure 7.2. Chest x-rays of a septic patient with acute respiratory distress syndrome before and after intravenous vitamin C 
(IVC) administration. IVC (200 mg/kg/d) was initiated on hospital day 4, and chest x-ray on day 5 revealed significantly 
improved opacities. (Images from Bharara, A. et al. 2016 Case Rep. Crit. Care. Article ID 8560871, 2016, 4p. CC-BY.)
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rOLE OF NEUtrOPHILS
Infiltration and activation of neutrophils in lung 
tissue in response to infection represent a primary 
mechanism for sepsis-induced pulmonary 
dysfunction and injury [69]. Activated neutrophils 
release reactive oxygen species, proteolytic 
enzymes, and other pro-inflammatory mediators 
that can directly damage tissues and prolong the 
inflammatory process [70]. Spent neutrophils 
normally undergo a process of programmed cell 
death known as apoptosis, which facilitates clearance 
of the neutrophils from sites of inflammation by 
phagocytosing macrophages [71]. This process 
prevents excessive tissue damage and supports 
resolution of inflammation. Attenuated neutrophil 
apoptosis has been reported in patients with 
sepsis, and this appears to be related to disease 
severity [72–74]. Delayed apoptosis may be due 
to the regulatory effects of pro-inflammatory 
mediators as well as oxidative inactivation of 
the redox-sensitive caspase effector enzymes 
[75,76]. Vitamin C may be able to decrease pro-
inflammatory mediator release during sepsis and 
also protect the oxidant-sensitive caspase enzymes 
in activated neutrophils, thereby protecting 
apoptotic cell death pathways [77,78]. In support of 
this premise, peritoneal neutrophils isolated from 
vitamin C–deficient Gulo knockout mice exhibited 
attenuated apoptosis and instead underwent 
necrotic cell death [79]. These vitamin  C–
deficient neutrophils were not phagocytosed by 
macrophages in vitro and persisted at inflammatory 
loci in vivo. Furthermore, Fisher et  al. reported 
that administration of 200 mg/kg vitamin C to 
mice attenuated peritonitis-induced sequestration 
of neutrophils, and decreased myeloperoxidase 
mRNA expression, in the lungs of the treated 
animals [62]. This was also associated with a lower 
acute lung injury score and decreased mortality in 
these animals. The clearance of neutrophils from 
sites of inflammation could conceivably contribute 
to the enhanced lung clearance observed in patients 
following vitamin C infusions (Figure 7.2).
Neutrophils that fail to undergo apoptosis 
instead undergo necrotic cell death. The 
subsequent release of intracellular components, 
such as proteases, can cause extensive tissue 
damage [70]. One recently identified form 
of neutrophil death, termed necroptosis, occurs 
when caspases are inactivated [80]. Necroptotic 
signaling pathways can result in the release of 
“neutrophil extracellular traps” (NETs) composed 
of neutrophil DNA, histones, and enzymes [81,82]. 
Although NETs have been proposed as a unique 
method of microbial killing [83], they have also 
been implicated in tissue damage and organ 
failure [84,85]. NET-associated histones can act 
as damage-associated molecular pattern proteins, 
activating the immune system and causing further 
tissue damage [86]. Patients with sepsis, or who 
go on to develop sepsis, have significantly elevated 
levels of circulating cell-free DNA, which is 
believed to be a marker of NET formation [84,87]. 
Preclinical studies in vitamin C–deficient Gulo 
knockout mice indicated enhanced NETs in the 
lungs of septic animals and increased circulating 
cell-free DNA [88]. The levels of these markers 
were attenuated in vitamin C–sufficient animals 
or in vitamin C–deficient animals that were 
administered vitamin C 30 minutes after induction 
of sepsis. The same investigators showed that in 
vitro supplementation of human neutrophils with 
vitamin C attenuated phorbol ester-induced NET 
formation [88]. Administration of gram doses of 
vitamin C to septic patients over 4 days, however, 
did not appear to decrease circulating cell-free 
DNA levels [89]. The duration of treatment may 
have been too short, or initiated too late in the 
inflammatory process, to provide a beneficial 
effect. It should also be noted that cell-free DNA 
is not specific for neutrophil-derived DNA, as it 
may also derive from necrotic tissue; however, 
the association of neutrophil-specific proteins 
or enzymes, such as myeloperoxidase, with the 
DNA can potentially provide an indication of its 
source [84].
Patients with severe infection also exhibit 
compromised neutrophil chemotactic activity that 
can compromise the cells’ ability to migrate to sites 
of infection [90,91]. This neutrophil “paralysis” is 
believed to be partly due to enhanced levels of 
immune-suppressive mediators released during 
the compensatory anti-inflammatory response 
observed following initial hyperstimulation 
of the immune system [92]. However, it is also 
possible that vitamin C depletion observed during 
severe infection may contribute. Support for this 
premise comes from studies in the 1980s and 
1990s that indicated that the impaired leukocyte 
chemotaxis observed in patients with recurrent 
infections could be restored in response to 
supplementation with gram doses of vitamin C 
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[93–98]. Furthermore, vitamin C supplementation 
of neonates with suspected sepsis dramatically 
improved neutrophil chemotaxis [99]. Patients 
with recurrent infections can also exhibit impaired 
neutrophil bacterial killing and phagocytosis, 
which can be significantly improved following 
supplementation with gram doses of vitamin C, 
resulting in long-lasting clinical improvement 
[93,94,97,98,100].
Neutrophils accumulate vitamin C against a 
concentration gradient resulting in levels 50- 
to 100-fold higher than plasma concentrations 
[101,102]. Active uptake of vitamin C occurs 
via specialized sodium-dependent vitamin C 
transporters (SVCTs) and can also occur following 
activation of the neutrophil oxidative burst and 
accumulation of the oxidized form of vitamin C, 
dehydroascorbic acid, via glucose transporters 
(GLUTs) [103]. It is believed that the accumulation 
of millimolar vitamin C concentrations indicates 
an important role for the vitamin within these 
cells, and depleted levels may compromise vital 
functions [77]. Vitamin C levels in leukocytes have 
been reported to decrease by half within 24 hours 
of subjects contracting an upper respiratory tract 
infection, and these levels were restored to normal 
when the infection resolved [104]. The investigators 
found that administration of 6 g/d of vitamin C 
during the infection could attenuate the decline in 
leukocyte vitamin C, although 200 mg/d did not 
affect the drop in vitamin C levels over the first 
few days of the infection. However, a randomized 
controlled trial in patients with acute respiratory 
infections administered 200 mg/d vitamin C 
showed repletion of neutrophil and mononuclear 
cell vitamin C levels within 2 weeks, whereas cells 
isolated from the placebo group remained low 
[22]. Thus, repletion of neutrophil vitamin C status 
via vitamin C administration during infection may 
enhance vital neutrophil functions [77].
MECHaNISMS OF aCtION
Vitamin C is a potent water-soluble antioxidant, 
able to scavenge a wide range of reactive oxygen 
species, thus protecting essential cellular 
structures, metabolic functions, and signaling 
pathways from oxidative damage [105,106]. 
Vitamin C also exhibits anti-inflammatory activity 
with inverse associations observed between 
vitamin C and pro-inflammatory cytokines and 
acute phase reactants such as C-reactive protein and 
procalcitonin [39,45,56,57,77]. Severe infection 
and sepsis are characterized by significant 
oxidative stress and overwhelming inflammatory 
mediators, sometimes referred to as a “cytokine 
storm” [107,108]. These stressors can contribute to 
the pathophysiology of sepsis, such as impaired 
microcirculatory flow, coagulopathy, capillary 
plugging, increased endothelial dysfunction and 
permeability, and multiorgan failure [109,110]. As 
such, the role of vitamin C in severe infection and 
sepsis has often focused on its antioxidant and anti-
inflammatory functions and effects on signaling 
pathways [109,110]. However, less attention has 
been paid to its role as an enzyme cofactor.
Biosynthetic Functions
One of the primary roles of vitamin C in the body is 
to act as a cofactor for a family of metalloenzymes 
with various biosynthetic and regulatory roles 
[111–113]. These enzymes introduce hydroxyl 
groups into biomolecules and comprise two 
main categories: iron- and 2-oxoglutarate–
dependent dioxygenases and copper-containing 
monooxygenases. Of the former category, 
vitamin C has long been known to act as a cofactor 
for the lysyl and prolyl hydroxylases required for 
stabilization of the tertiary structure of collagen, 
an essential component of the vasculature [114]. 
Vitamin C may also be able to stimulate the 
expression of collagen mRNA, perhaps through 
its gene regulatory mechanisms described later 
[77]. Similarly, vitamin C is a cofactor for the two 
hydroxylases involved in carnitine biosynthesis, a 
molecule required for transport of fatty acids into 
mitochondria for generation of metabolic energy 
[115]. Mitochondrial dysfunction and depleted ATP 
levels are observed in sepsis; thus, vitamin C may 
be able to contribute to metabolic resuscitation 
via both antioxidant and cofactor mechanisms 
[116,117].
Vitamin C is also known to facilitate the synthesis 
of the catecholamines dopamine, norepinephrine, 
and epinephrine within the sympathetic nervous 
system and adrenal medulla. These catecholamines 
are central to the cardiovascular response to severe 
infection; they increase arterial pressure through 
binding to α-adrenergic receptors on the smooth 
muscle cells of the vasculature and can promote 
increased cardiac contractility and heart rate 
through binding to β-adrenergic receptors on 
cardiac muscle [118]. Vitamin C is a cofactor for 
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the copper-containing monooxygenase dopamine 
β-hydroxylase that introduces a hydroxyl group 
onto dopamine to form norepinephrine (Figure 7.3) 
[119,120]. Epinephrine is subsequently synthesized 
in the adrenal glands via methylation of the amine 
group of norepinephrine. Recent research indicates 
that vitamin C may also stimulate the rate-limiting 
enzyme tyrosine hydroxylase via recycling the 
enzyme’s cofactor, tetrahydrobiopterin, thus 
facilitating hydroxylation of L-tyrosine to form 
the dopamine precursor L-dopa (Figure 7.3) [121]. 
Some evidence also suggests that vitamin C may 
enhance the synthesis of tyrosine hydroxylase 
[121]; this is possibly through its gene-regulatory 
effects, as described below.
It is noteworthy that the tissues where the 
catecholamines are synthesized (i.e., the brain 
and adrenal glands) contain the highest levels 
of vitamin C in the body [122], indicating that 
the vitamin plays a vital role in these organs. 
Furthermore, animal models of vitamin C 
deficiency have shown significant retention 
of the vitamin in the brain during dietary 
depletion [123–125], supporting the importance 
of vitamin  C in the central nervous system. 
Impaired adrenal hormone synthesis has been 
observed in critically ill patients and is probably a 
common complication in severe sepsis [126,127]. 
Interestingly, norepinephrine levels are decreased 
in vitamin C–deficient animal models, particularly 
in the adrenal glands [128–130]. Research has 
shown that vitamin C is also secreted from the 
adrenal glands as part of the stress response 
[131], which could conceivably result in adrenal 
vitamin C depletion under conditions of sustained 
stress. Thus, appropriate supplementation of 
vitamin C in sepsis may support endogenous 











































Figure 7.3. Vitamin C–dependent synthesis of the catecholamine vasopressors dopamine, norepinephrine, and 
epinephrine. Vitamin C acts as a cofactor for the metallo-enzyme dopamine β-hydroxylase and also recycles 
tetrahydrobiopterin, a cofactor for the rate-limiting enzyme tyrosine hydroxylase. (AH− ascorbate, DHA dehydroascorbic 
acid, BH4 tetrahydrobiopterin, BH2 dihydrobiopterin.)
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Vitamin C is also a cofactor for the copper-
containing enzyme peptidylglycine α-amidating 
monooxygenase (PAM) that is required for the 
synthesis of amidated neuropeptide hormones 
[132]. The carboxy-terminal amine group of 
amidated peptides is essential for their biological 
activities [133]. One of these amidated peptide 
hormones is vasopressin, also known as arginine 
vasopressin (AVP) or antidiuretic hormone (ADH), 
which is synthesized in the hypothalamus, 
posttranslationally modified by PAM, and then 
stored in the posterior pituitary [134]. Vasopressin 
is secreted in response to decreased blood 
volume or arterial pressure or increased plasma 
osmolality. It interacts with specific receptors 
expressed by vascular smooth muscle cells and 
kidney collecting ducts to cause vasoconstriction 
and water retention, respectively [135]. The 
hormone is synthesized as a pre-prohormone that 
undergoes sequential cleavage steps to produce 
provasopressin and finally a glycine-extended 
precursor. The carboxy-terminal glycine residue 
of the vasopressin precursor subsequently 
undergoes posttranslational modification by the 
vitamin C–dependent enzyme PAM to generate 
the active carboxy-amidated hormone (Figure 7.4). 
Support for a connection between vitamin C and 
vasopressin biosynthesis comes from an animal 
study, whereby centrally administered vitamin C 
enhanced circulating levels of vasopressin and 
induced antidiuresis [136].
Circulating vasopressin levels increase 
dramatically during the initial phase of septic 
shock, but this is followed by a significant decline 
in the latter phase [137,138]. Patients in late-phase 
septic shock have significantly lower levels of 
circulating vasopressin compared with patients 
in cardiogenic shock, despite similar hypotension 
[138]. The decline in circulating vasopressin levels 
after the onset of septic shock is due to depletion 
of pituitary stores and possibly also impaired 
vasopressin synthesis [139]. It is of interest to note 
that the pituitary gland, where the enzyme PAM 
is abundantly expressed, has the highest levels of 
vitamin C in the body [122]. Thus, it is conceivable 
that the depleted vitamin C status of patients with 
sepsis could contribute to the observed decrease in 
vasopressin biosynthesis [137–139]. Furthermore, 
pro-vasopressin, which lacks the carboxyterminal 
amine of mature vasopressin, is significantly 
associated with mortality in patients with 
pneumonia and septic shock, with higher levels 
observed in nonsurvivors than survivors [140,141]. 
Although pro-vasopressin has enhanced stability in 
circulation, the higher ratio of pro-vasopressin to 
mature vasopressin could also be due to decreased 
posttranslational activation of the hormone by 
PAM because of limited cofactor availability. This 
premise is supported by the observation that other 
peptide pro-hormones that are substrates of PAM 
(e.g., pro-adrenomedullin and procalcitonin) 
are also elevated in severe infectious conditions, 
particularly in nonsurvivors [141–143]. It is 
interesting to note that elevated procalcitonin 
levels decrease following administration of 






















































Figure 7.4. Vitamin C–dependent synthesis of mature 
carboxy-terminal amidated vasopressin. Vitamin C 
is a cofactor for the metallo-enzyme peptidylglycine 
α-amidating monooxygenase (PAM). The enzyme 
comprises two domains: a copper-dependent 
monooxygenase domain, which converts glycine-
extended peptides into hydroxyglycine intermediates; 
and a lyase domain, which converts the hydroxyglycine 
intermediates into amidated products. (AH− ascorbate, 
DHA dehydroascorbic acid.)
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Septic shock is normally managed through the 
administration of catecholamine vasopressors, 
primarily norepinephrine, to elevate mean 
arterial pressure to ≥65 mm Hg [144]. Vasopressin 
administration is also recommended in the 
Surviving Sepsis Campaign guidelines to raise 
mean arterial pressure to target or to decrease the 
norepinephrine dose [28]. Exogenous vasopressor 
administration to patients with septic shock, 
however, can result in adverse side effects such as 
tissue ischemia and resultant necrosis. Based on 
the evidence presented earlier, we hypothesized 
that administration of vitamin C to patients with 
septic shock may decrease the requirement for 
exogenously administered vasopressors, through 
acting as a cofactor for in vivo enzyme-dependent 
synthesis of norepinephrine and vasopressin [59]. 
Our hypothesis has been supported by four recent 
clinical trials that showed deceased vasopressor 
and norepinephrine requirements (both dose and 
duration) following administration of 6–7 g/d 
of intravenous vitamin C to patients with severe 
sepsis and septic shock [52,53,56,57]. Other trials 
are currently underway to confirm these findings.
Gene regulatory Functions
Recent research has uncovered new roles for 
vitamin C in the regulation of transcription 
factor activity and epigenetic marks, thus 
influencing gene transcription and cell signaling 
pathways [112,113]. For example, the iron- and 
2-oxoglutarate–dependent asparagyl and prolyl 
hydroxylases required for the downregulation of 
the transcription factor hypoxia-inducible factor-1α 
(HIF-1α) utilize vitamin C as a cofactor [112]. 
HIF-1α is a constitutively expressed transcription 
factor that regulates numerous genes, including 
those involved in energy metabolism, angiogenic 
signaling, and vasomotor regulation [145]. Under 
normoxic conditions, HIF-1α is downregulated 
via hydroxylase-mediated posttranslational 
modifications that prevent coactivator binding 
and target HIF for proteosomal degradation 
[146]. During the hypoxia and ischemia observed 
with acute lung infections and sepsis, HIF is 
upregulated due to the absence of substrates (e.g., 
oxygen) and cofactors (e.g., vitamin C) required 
for hydroxylase-dependent downregulation. 
Although initially beneficial to the host, prolonged 
upregulation of HIF can result in pulmonary 
hypertension and edema [147]. HIF also facilitates 
neutrophil survival at hypoxic loci through 
delaying apoptosis [148]. In vitamin C–deficient 
Gulo knockout mice, upregulation of HIF-1α was 
observed under normoxic conditions, along with 
attenuated neutrophil apoptosis and clearance by 
macrophages [79]. HIF-1α has also been proposed 
as a regulator of NET release by neutrophils [149], 
thus providing a potential mechanism by which 
vitamin C could downregulate NET generation by 
these cells [88].
More recently, an important role for vitamin C 
has emerged in the regulation of DNA and histone 
demethylation by acting as a cofactor for iron- 
and 2-oxoglutarate–dependent enzymes that 
hydroxylate methylated epigenetic marks [113]. 
Vitamin C acts as a cofactor for the ten-eleven 
translocation (TET) dioxygenases that hydroxylate 
methylated cytosine moieties in DNA [150–152]. 
The hydroxymethylcytosine mark can be further 
oxidized and subsequently removed through both 
active and passive DNA repair mechanisms but 
may also represent an epigenetic mark in its own 
right [153]. Vitamin C is also a cofactor for several 
Jumonji C domain-containing histone demethylases 
(JHDMs) that catalyze histone demethylation 
[154]. Methylation of lysine and arginine residues 
on histones is closely associated with activation or 
silencing of transcription. JHDMs can hydroxylate 
mono-, di-, and trimethylated histone lysine and 
arginine residues, resulting in demethylation, 
and vitamin C is required for optimal catalytic 
activity and demethylation by JHDMs [155,156]. 
The involvement of vitamin C in JHDM-dependent 
histone demethylation was confirmed in somatic 
cell reprogramming [157,158]. It is likely that 
the gene regulatory functions of vitamin C play 
major roles in its immune-regulating functions. 
For example, preliminary evidence indicates 
that vitamin C can regulate T-cell maturation via 
epigenetic mechanisms involving the TETs and 
histone demethylation [159–161]. Supplementation 
of healthy volunteers with vitamin C was found 
to modulate ex vivo lipopolysaccharide-stimulated 
gene expression in mononuclear cells, specifically 
enhancing synthesis of the anti-inflammatory 
cytokine interleukin-10 [162]. Due to the 
thousands of genes regulated via both DNA and 
histone demethylation, epigenomic regulation by 
vitamin C likely plays a major role in its pleiotropic 
health-promoting and disease-modifying effects.
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CONCLUSIONS aND FUtUrE DIrECtIONS
Vitamin C has a myriad of functions that appear 
to contribute to beneficial outcomes in severe 
respiratory infections, such as pneumonia, and 
the potentially life-threatening condition of sepsis. 
These include acting as a scavenger of reactive 
oxygen species and a modulator of inflammatory 
mediators, as well as a cofactor for a variety of 
biosynthetic and regulatory enzymes, with the 
potential to modulate the transcription of thousands 
of genes and numerous cell signaling pathways. 
Observational studies indicate that patients with 
severe respiratory infections and sepsis have 
depleted vitamin C status during their illness, 
including a high prevalence of deficiency, despite 
recommended intakes. This suggests that these 
patients have higher requirements for vitamin C, 
which has been borne out in small interventional 
studies indicating that gram doses of vitamin C 
are required to normalize the vitamin  C status 
of critically ill patients. Although optimal dietary 
intakes of vitamin C (i.e., 200 mg/d) may decrease 
the risk of developing a respiratory infection 
[16,163], it appears that successively higher 
amounts of vitamin C are required as infectious 
diseases progress in severity (Figure 7.5). A handful 
of small randomized controlled trials indicate 
that administration of gram doses of vitamin C 
to patients with pneumonia and sepsis improves 
multiorgan function, particularly the pulmonary, 
cardiovascular, and renal systems, as well as 
potentially decreases mortality rates. Currently, 
larger interventional studies are underway to 
confirm the effects of vitamin C on mortality. If 
these trials support the initially promising findings 
of the smaller studies, there would then be strong 
justification to introduce vitamin C administration 
into routine clinical practice for these conditions, 
as well as to assess the effects of vitamin C 
administration on related infectious conditions. 
Unlike many drugs that target only one specific 
biochemical pathway, vitamin C targets multiple 
pathways and hence can exhibit body-wide effects.
To date, there have been no studies that have 
assessed the effects of vitamin C intervention 
on the long-term quality-of-life outcomes of 
patients with pneumonia and sepsis (Figure 7.5). 
The reported vitamin C–dependent decreases in 
organ dysfunction, including decreased acute 
renal failure, which normally requires ongoing 
dialysis or a transplant, would be expected to 
significantly improve long-term patient quality 
of life. The human brain has a particularly high 
requirement for vitamin C, and both observational 
and interventional studies have shown inverse 
associations between vitamin C and cognitive 
dysfunction and psychiatric disorders such as 
depression and anxiety [165,166]. Furthermore, 
vitamin C may be able to modulate the stress 
response with inverse associations observed 
between vitamin C status and cortisol levels, 
1. Prevention of infections
2. Prevent onset of sepsis
3. Treatment of acute sepsis
Vitamin C dose
≥200 mg/d oral
2–3 g/d oral or IV
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Figure 7.5. Vitamin C requirements during severe infection. The requirements for vitamin C increase during the 
progression from prevention of infection to treatment of acute sepsis. (Adapted from Carr, A. C. 2018. Crit. Care 22, 247.)
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and decreased cortisol levels reported following 
vitamin C intervention [167]. Most of the 
vitamin  C interventional studies carried out in 
critically ill patients have been for a total duration 
of 4 days, which may not be sufficient to have a 
dramatic effect on quality of life at 3 or 6 months 
later due to the rapid return of vitamin C levels to 
baseline following withdrawal of supplementation 
[43,168]. Because vitamin C is water soluble and 
is not retained by the body, sustained long-term 
quality-of-life effects will likely require ongoing 
vitamin C supplementation.
Vitamin C administration has been shown 
to improve the quality of life and decrease the 
symptoms of oncology patients, likely through 
repletion of inadequate vitamin C levels and 
decrease of the off-target toxicity and adverse side 
effects of chemotherapeutic drugs [169]. Animal 
studies have indicated that administration of drugs 
such as sedatives, analgesics, and muscle relaxants 
to vitamin C–synthesizing animals stimulates 
an increased synthesis/excretion of the vitamin, 
suggesting a higher requirement for vitamin C 
due to enhanced metabolism when drugs are 
administered [170,171]. Klenner also reported that 
penicillin had a retarding effect on the action of 
vitamin C in patients with pneumonia, and in one 
case, beneficial effects were not obtained until 
the penicillin was discontinued [24]. Therefore, 
it is conceivable that administration of additional 
vitamin C to patients with sepsis may counteract 
some of the adverse effects of the many drugs that 
are administered to these patients during intensive 
care. The effects of vitamin C on drug-related side 
effects and long-term patient quality of life should 
be assessed in further clinical trials of patients 
with severe respiratory infections and sepsis.
aCKNOWLEDGMENtS
Thank you to Dr. Paul Marik for critically 
reviewing the manuscript. The author is supported 
by a Health Research Council of New Zealand Sir 
Charles Hercus Health Research Fellowship.
rEFErENCES
 1. Hemilä, H. 2017. Vitamin C and infections. 
Nutrients 9, E339.
 2. Duggan, C. P., Westra, S. J. and Rosenberg, A. E. 
2007. Case records of the Massachusetts General 
Hospital. Case 23-2007. A 9-year-old boy with 
bone pain, rash, and gingival hypertrophy. 
N. Engl. J. Med. 357, 392–400.
 3. Khalid, M. M. 2009. Scurvy; radiological 
diagnosis. Prof. Med. J. 16, 466–468.
 4. Doll, S. and Ricou, B. 2013. Severe vitamin C 
deficiency in a critically ill adult: A case report. 
Eur. J. Clin. Nutr. 67, 881–882.
 5. Ramar, S., Sivaramakrishnan, V. and Manoharan, 
K. 1993. Scurvy—A forgotten disease. Arch. Phys. 
Med. Rehabil. 74, 92–95.
 6. Jensen, P. O., Lykkesfeldt, J., Bjarnsholt, T., 
Hougen, H. P., Hoiby, N. and Ciofu, O. 2012. Poor 
antioxidant status exacerbates oxidative stress 
and inflammatory response to pseudomonas 
aeruginosa lung infection in guinea pigs. Basic 
Clin. Pharmacol. Toxicol. 110, 353–358.
 7. Gaut, J. P., Belaaouaj, A., Byun, J., Roberts, 
L.  J. 2nd, Maeda, N., Frei, B. and Heinecke, 
J. W. 2006. Vitamin C fails to protect amino 
acids and lipids from oxidation during acute 
inflammation. Free Radic. Biol. Med. 40, 1494–1501.
 8. Li, W., Maeda, N. and Beck, M. A. 2006. Vitamin 
C deficiency increases the lung pathology of 
influenza virus-infected gulo−/− mice. J. Nutr. 
136, 2611–2616.
 9. Buffinton, G. D., Christen, S., Peterhans, E. and 
Stocker, R. 1992. Oxidative stress in lungs of 
mice infected with influenza A virus. Free Radic. 
Res. Commun. 16, 99–110.
 10. Hennet, T., Peterhans, E. and Stocker, R. 1992. 
Alterations in antioxidant defences in lung and 
liver of mice infected with influenza A virus. 
J. Gen. Virol. 73 (Pt 1), 39–46.
 11. Musher, D. M. and Thorner, A. R. 2014. 
Community-acquired pneumonia. N. Engl. J. Med. 
371, 1619–1628.
 12. Levy, M. L., Le Jeune, I., Woodhead, M. A., 
Macfarlaned, J. T. and Lim, W. S. 2010. Primary 
care summary of the British Thoracic Society 
Guidelines for the management of community 
acquired pneumonia in adults: 2009. update. 
Endorsed by the Royal College of General 
Practitioners and the Primary Care Respiratory 
Society UK. Prim. Care Respir. J. 19, 21–27.
 13. GBD 2016 Causes of Death Collaborators. 2017. 
Global, regional, and national age-sex specific 
mortality for 264 causes of death, 1980-2016: 
A systematic analysis for the Global Burden of 
Disease Study 2016. Lancet 390, 1151–1210.
 14. GBD 2016 Lower Respiratory Infections 
Collaborators. 2018. Estimates of the global, 
regional, and national morbidity, mortality, and 
129VItaMIN C IN PNEUMONIa aND SEPSIS
aetiologies of lower respiratory infections in 195 
countries, 1990–2016: A systematic analysis for 
the Global Burden of Disease Study 2016. Lancet 
Infect. Dis 18(11), 1191–1210.
 15. Burton, D. C., Flannery, B., Bennett, N. M., 
Farley, M. M., Gershman, K., Harrison, L. H., 
Lynfield, R. et  al. 2010. Socioeconomic and 
racial/ethnic disparities in the incidence of 
bacteremic pneumonia among US adults. Am. J. 
Public Health 100, 1904–1911.
 16. Hemilä, H. and Louhiala, P. 2013. Vitamin C 
for preventing and treating pneumonia. Cochrane 
database Syst. Rev. 8, Cd005532.
 17. Glazebrook, A. J. and Thomson, S. 1942. The 
administration of vitamin C in a large institution 
and its effect on general health and resistance to 
infection. J. Hyg. (Lond.) 42, 1–19.
 18. Kimbarowski, J. A. and Mokrow, N. J. 1967. 
Colored precipitation reaction of the urine 
according to Kimbarowski (FARK) as an index 
of the effect of ascorbic acid during treatment 
of viral influenza (English translation: http://
www.mv.helsinki.fi/home/hemila/T4.pdf). 
Dtsch. Gesundheitsw. 22, 2413–2418.
 19. Pitt, H. A. and Costrini, A. M. 1979. Vitamin 
C prophylaxis in marine recruits. JAMA 241, 
908–911.
 20. Bakaev, V. V. and Duntau, A. P. 2004. Ascorbic 
acid in blood serum of patients with pulmonary 
tuberculosis and pneumonia. Int. J. Tuberc. Lung 
Dis. 8, 263–266.
 21. Chakrabarti, B. and Banerjee, S. 1955. 
Dehydroascorbic acid level in blood of patients 
suffering from various infectious diseases. Proc. 
Soc. Exp. Biol. Med. 88, 581–583.
 22. Hunt, C., Chakravorty, N. K., Annan, G., 
Habibzadeh, N. and Schorah, C. J. 1994. The 
clinical effects of vitamin C supplementation 
in elderly hospitalised patients with acute 
respiratory infections. Int. J. Vitam. Nutr. Res. 64, 
212–219.
 23. Mochalkin, N. I. 1970. Ascorbic acid in the 
complex therapy of acute pneumonia (English 
translation: http://www.mv.helsinki.fi/home/
hemila/T5.pdf). Voen. Med. Zh. 9, 17–21.
 24. Klenner, F. R. 1948. Virus pneumonia and its 
treatment with vitamin C. South. Med. Surg. 110, 
36–38.
 25. Kim, W. Y., Jo, E. J., Eom, J. S., Mok, J., Kim, M. 
H., Kim, K. U., Park, H. K., Lee, M. K. and Lee, 
K. 2018. Combined vitamin C, hydrocortisone, 
and thiamine therapy for patients with severe 
pneumonia who were admitted to the intensive 
care unit: Propensity score-based analysis of a 
before-after cohort study. J. Crit. Care. 47, 211–218.
 26. Cathcart, R. F. 1981. Vitamin C, titrating to 
bowel tolerance, anascorbemia, and acute 
induced scurvy. Med. Hypotheses 7, 1359–1376.
 27. Singer, M., Deutschman, C. S., Seymour, C. 
W., Shankar-Hari, M., Annane, D., Bauer, M., 
Bellomo, R. et al. 2016. The third international 
consensus definitions for sepsis and septic shock 
(Sepsis-3). JAMA 315, 801–810.
 28. Rhodes, A., Evans, L. E., Alhazzani, W., Levy, 
M. M., Antonelli, M., Ferrer, R., Kumar, A. et al. 
2017. Surviving sepsis campaign: International 
guidelines for management of sepsis and septic 
shock: 2016. Crit. Care Med. 45, 486–552.
 29. Fleischmann, C., Scherag, A., Adhikari, N. K., 
Hartog, C. S., Tsaganos, T., Schlattmann, P., 
Angus, D. C. and Reinhart, K. 2016. Assessment 
of global incidence and mortality of hospital-
treated sepsis. Current estimates and limitations. 
Am. J. Respir. Crit. Care Med. 193, 259–272.
 30. Vincent, J. L., Marshall, J. C., Namendys-Silva, 
S. A., Francois, B., Martin-Loeches, I., Lipman, 
J., Reinhart, K. et  al. 2014. Assessment of the 
worldwide burden of critical illness: The 
Intensive Care Over Nations (ICON) audit. Lancet 
Respir. Med. 2, 380–386.
 31. Gaieski, D. F., Edwards, J. M., Kallan, M. J. and 
Carr, B. G. 2013. Benchmarking the incidence 
and mortality of severe sepsis in the United 
States. Crit. Care Med. 41, 1167–1174.
 32. Stevenson, E. K., Rubenstein, A. R., Radin, G. 
T., Wiener, R. S. and Walkey, A. J. 2014. Two 
decades of mortality trends among patients with 
severe sepsis: A comparative meta-analysis. Crit. 
Care Med. 42, 625–631.
 33. Kaukonen, K. M., Bailey, M., Suzuki, S., Pilcher, 
D. and Bellomo, R. 2014. Mortality related to 
severe sepsis and septic shock among critically 
ill patients in Australia and New Zealand, 2000–
2012. JAMA 311, 1308–1316.
 34. Finfer, S., Bellomo, R., Lipman, J., French, C., 
Dobb, G. and Myburgh, J. 2004. Adult-population 
incidence of severe sepsis in Australian and New 
Zealand intensive care units. Intensive Care Med. 30, 
589–596.
 35. Gotts, J. E. and Matthay, M. A. 2016. Sepsis: 
Pathophysiology and clinical management. BMJ 
353, i1585.
130 VItaMIN C
 36. Prescott, H. C. and Angus, D. C. 2018. Enhancing 
recovery from sepsis: A review. JAMA 319, 62–75.
 37. Schorah, C. J., Downing, C., Piripitsi, A., 
Gallivan, L., Al-Hazaa, A. H., Sanderson, M. 
J. and Bodenham, A. 1996. Total vitamin 
C, ascorbic acid, and dehydroascorbic acid 
concentrations in plasma of critically ill patients. 
Am. J. Clin. Nutr. 63, 760–765.
 38. McGregor, G. P. and Biesalski, H. K. 2006. 
Rationale and impact of vitamin C in clinical 
nutrition. Curr. Opin. Clin. Nutr. Metab. Care 9, 
697–703.
 39. Carr, A. C., Rosengrave, P. C., Bayer, S., 
Chambers, S., Mehrtens, J. and Shaw, G. M. 2017. 
Hypovitaminosis C and vitamin C deficiency 
in critically ill patients despite recommended 
enteral and parenteral intakes. Crit. Care. 21, 300.
 40. Borrelli, E., Roux-Lombard, P., Grau, G. E., 
Girardin, E., Ricou, B., Dayer, J. and Suter, P. M. 
1996. Plasma concentrations of cytokines, their 
soluble receptors, and antioxidant vitamins can 
predict the development of multiple organ failure 
in patients at risk. Crit. Care Med. 24, 392–397.
 41. Long, C. L., Maull, K. I., Krishnan, R. S., Laws, 
H. L., Geiger, J. W., Borghesi, L., Franks, W., 
Lawson, T. C. and Sauberlich, H. E. 2003. 
Ascorbic acid dynamics in the seriously ill and 
injured. J. Surg. Res. 109, 144–148.
 42. Nathens, A. B., Neff, M. J., Jurkovich, G. J., 
Klotz, P., Farver, K., Ruzinski, J. T., Radella, F., 
Garcia, I. and Maier, R. V. 2002. Randomized, 
prospective trial of antioxidant supplementation 
in critically ill surgical patients. Ann. Surg. 236, 
814–822.
 43. de Grooth, H. J., Manubulu-Choo, W. P., 
Zandvliet, A. S., Spoelstra-de Man, A. M. E., 
Girbes, A. R., Swart, E. L. and Oudemans-
van Straaten, H. M. 2018. Vitamin-C 
pharmacokinetics in critically ill patients: A 
randomized trial of four intravenous regimens. 
Chest. 153(6), 1368–1377.
 44. Levine, M., Conry-Cantilena, C., Wang, Y., 
Welch, R. W., Washko, P. W., Dhariwal, 
K. R., Park, J. B. et  al. 1996. Vitamin C 
pharmacokinetics in healthy volunteers: 
Evidence for a recommended dietary allowance. 
Proc. Natl. Acad. Sci. USA 93, 3704–3709.
 45. Fowler, A. A., Syed, A. A., Knowlson, S., 
Sculthorpe, R., Farthing, D., DeWilde, C., 
Farthing, C. A. et al. 2014. Phase I safety trial of 
intravenous ascorbic acid in patients with severe 
sepsis. J. Transl. Med. 12, 32.
 46. Doise, J. M., Aho, L. S., Quenot, J. P., Guilland, J. 
C., Zeller, M., Vergely, C., Aube, H., Blettery, B. 
and Rochette, L. 2008. Plasma antioxidant status 
in septic critically ill patients: A decrease over 
time. Fundam. Clin. Pharmacol. 22, 203–209.
 47. Voigt, K., Kontush, A., Stuerenburg, H. J., 
Muench-Harrach, D., Hansen, H. C. and Kunze, 
K. 2002. Decreased plasma and cerebrospinal 
fluid ascorbate levels in patients with septic 
encephalopathy. Free Radic. Res. 36, 735–739.
 48. Collier, B. R., Giladi, A., Dossett, L. A., Dyer, L., 
Fleming, S. B. and Cotton, B. A. 2008. Impact of 
high-dose antioxidants on outcomes in acutely 
injured patients. JPEN J. Parenter. Enteral Nutr. 32, 
384–388.
 49. Berger, M. M., Soguel, L., Shenkin, A., Revelly, 
J. P., Pinget, C., Baines, M. and Chiolero, R. L. 
2008. Influence of early antioxidant supplements 
on clinical evolution and organ function in 
critically ill cardiac surgery, major trauma, and 
subarachnoid hemorrhage patients. Crit. Care 12, 
R101.
 50. Giladi, A. M., Dossett, L. A., Fleming, S. B., 
Abumrad, N. N. and Cotton, B. A. 2011. High-
dose antioxidant administration is associated 
with a reduction in post-injury complications 
in critically ill trauma patients. Injury 42, 
78–82.
 51. Sandesc, M., Rogobete, A. F., Bedreag, O. 
H., Dinu, A., Papurica, M., Cradigati, C. A., 
Sarandan, M. et al. 2018. Analysis of oxidative 
stress-related markers in critically ill polytrauma 
patients: An observational prospective single-
center study. Bosn. J. Basic Med. Sci. 18(2), 191–197.
 52. Zabet, M. H., Mohammadi, M., Ramezani, 
M. and Khalili, H. 2016. Effect of high-dose 
ascorbic acid on vasopressor’s requirement in 
septic shock. J. Res. Pharm. Pract. 5, 94–100.
 53. Nabil Habib, T. and Ahmed, I. 2017. Early 
adjuvant intravenous vitamin C treatment 
in septic shock may resolve the vasopressor 
dependence. Int. J. Microbiol. Adv. Immunol. 05, 
77–81.
 54. Litwak, J. J., Cho, N., Nguyen, H. B., Moussavi, K. 
and Bushell, T. 2019. Vitamin C, hydrocortisone, 
and thiamine for the treatment of severe sepsis 
and septic shock: A retrospective analysis of 
real-world application. J. Clin. Med. 8.
 55. Shin, T. G., Kim, Y. J., Ryoo, S. M., Hwang, S. Y., 
Jo, I. J., Chung, S. P., Choi, S. H., Suh, G. J. and 
Kim, W. Y. 2019. Early vitamin C and thiamine 
administration to patients with septic shock in 
131VItaMIN C IN PNEUMONIa aND SEPSIS
emergency departments: Propensity score-based 
analysis of a before-and-after cohort study. J. 
Clin. Med. 8.
 56. Balakrishnan, M., Gandhi, H., Shah, K., Pandya, 
H., Patel, R., Keshwani, S. and Yadav, N. 2018. 
Hydrocortisone, vitamin C and thiamine for the 
treatment of sepsis and septic shock following 
cardiac surgery. Indian J. Anaesth. 62, 934–939.
 57. Marik, P. E., Khangoora, V., Rivera, R., Hooper, 
M. H. and Catravas, J. 2017. Hydrocortisone, 
vitamin C, and thiamine for the treatment of 
severe sepsis and septic shock: A retrospective 
before-after study. Chest 151, 1229–1238.
 58. Carr, A. C. 2019. Duration of intravenous 
vitamin C therapy is a critical consideration. Crit. 
Care Resusc. 21(3), 220–221.
 59. Carr, A. C., Shaw, G. M., Fowler, A. A. and 
Natarajan, R. 2015. Ascorbate-dependent 
vasopressor synthesis: A rationale for vitamin C 
administration in severe sepsis and septic shock? 
Crit. Care 19, e418.
 60. Fein, A. M. and Calalang-Colucci, M. G. 2000. 
Acute lung injury and acute respiratory distress 
syndrome in sepsis and septic shock. Crit. Care 
Clin. 16, 289–317.
 61. Zemans, R. L. and Matthay, M. A. 2004. Bench-
to-bedside review: The role of the alveolar 
epithelium in the resolution of pulmonary 
edema in acute lung injury. Crit. Care 8, 
469–477.
 62. Fisher, B. J., Kraskauskas, D., Martin, E. J., 
Farkas, D., Wegelin, J. A., Brophy, D., Ward, 
K. R., Voelkel, N. F., Fowler, A. A.3rd, and 
Natarajan, R. 2012. Mechanisms of attenuation 
of abdominal sepsis induced acute lung injury 
by ascorbic acid. Am. J. Physiol. Lung Cell Mol. Physiol. 
303, L20–L32.
 63. Mutlu, G. M. and Sznajder, J. I. 2005. Mechanisms 
of pulmonary edema clearance. Am. J. Physiol. Lung 
Cell Mol. Physiol. 289, L685–L695.
 64. Barabutis, N., Khangoora, V., Marik, P. E. 
and Catravas, J. D. 2017. Hydrocortisone 
and ascorbic acid synergistically prevent and 
repair lipopolysaccharide-induced pulmonary 
endothelial barrier dysfunction. Chest 152, 
954–962.
 65. Bharara, A., Grossman, C., Grinnan, D., Syed, 
A. A., Fisher, B. J., DeWilde, C., Natarajan, R. 
and Fowler, A. A. 2016. Intravenous vitamin C 
administered as adjunctive therapy for recurrent 
acute respiratory distress syndrome. Case Rep. Crit. 
Care Article ID 8560871, 2016, 4p.
 66. Fowler, A. A., Kim, C., Lepler, L., Malhotra, R., 
Debesa, O., Natarajan, R., Fisher, B. J. et al. 2017. 
Intravenous vitamin C as adjunctive therapy 
for enterovirus/rhinovirus induced acute 
respiratory distress syndrome. World J. Crit. Care 
Med. 6, 85–90.
 67. Marik, P. E. and Long, A. 2018. ARDS 
complicating pustular psoriasis: Treatment 
with low-dose corticosteroids, vitamin C and 
thiamine. BMJ Case Rep. 2018.
 68. Gurganus, M. M., Marik, P. E. and Varon, 
J. 2019. The successful treatment of severe 
aspiration pneumonitis with the combination 
of hydrocortisone, ascorbic acid, and thiamine. 
Crit. Care Shock 22, 57–61.
 69. Brown, K. A., Brain, S. D., Pearson, J. D., 
Edgeworth, J. D., Lewis, S. M. and Treacher, D. 
F. 2006. Neutrophils in development of multiple 
organ failure in sepsis. Lancet 368, 157–169.
 70. Pechous, R. D. 2017. With friends like these: 
The complex role of neutrophils in the pro-
gression of severe pneumonia. Front. Cell. Infect. 
Microbiol. 7, 160.
 71. Fox, S., Leitch, A. E., Duffin, R., Haslett, C. 
and Rossi, A. G. 2010. Neutrophil apoptosis: 
Relevance to the innate immune response and 
inflammatory disease. J. Innate. Immun. 2, 216–227.
 72. Taneja, R., Parodo, J., Jia, S. H., Kapus, A., 
Rotstein, O. D. and Marshall, J. C. 2004. Delayed 
neutrophil apoptosis in sepsis is associated with 
maintenance of mitochondrial transmembrane 
potential and reduced caspase-9 activity. Crit. 
Care Med. 32, 1460–1469.
 73. Tamayo, E., Gomez, E., Bustamante, J., 
Gomez-Herreras, J. I., Fonteriz, R., Bobillo, F., 
Bermejo-Martin, J. F. et al. 2012. Evolution of 
neutrophil apoptosis in septic shock survivors 
and nonsurvivors. J. Crit. Care 27, 415.e1–415.e11.
 74. Fialkow, L., Fochesatto Filho, L., Bozzetti, M. C., 
Milani, A. R., Rodrigues Filho, E. M., Ladniuk, 
R. M., Pierozan, P. et  al. 2006. Neutrophil 
apoptosis: A marker of disease severity in sepsis 
and sepsis-induced acute respiratory distress 
syndrome. Crit. Care 10, R155.
 75. Colotta, F., Re, F., Polentarutti, N., Sozzani, 
S. and Mantovani, A. 1992. Modulation of 
granulocyte survival and programmed cell 
death by cytokines and bacterial products. Blood 
80, 2012–2020.
 76. Wilkie, R. P., Vissers, M. C., Dragunow, M. and 
Hampton, M. B. 2007. A functional NADPH 
oxidase prevents caspase involvement in the 
132 VItaMIN C
clearance of phagocytic neutrophils. Infect. 
Immun. 75, 3256–3263.
 77. Carr, A. C. and Maggini, S. 2017. Vitamin C and 
immune function. Nutrients 9.
 78. Vissers, M. C. and Hampton, M. B. 2004. The 
role of oxidants and vitamin C on neutrophil 
apoptosis and clearance. Biochem. Soc. Trans. 32, 
499–501.
 79. Vissers, M. C. and Wilkie, R. P. 2007. Ascorbate 
deficiency results in impaired neutrophil 
apoptosis and clearance and is associated with 
up-regulation of hypoxia-inducible factor 
1alpha. J. Leukoc. Biol. 81, 1236–1244.
 80. Wang, X., Yousefi, S. and Simon, H. U. 
2018. Necroptosis and neutrophil-associated 
disorders. Cell Death Dis. 9, 111.
 81. Desai, J., Mulay, S. R., Nakazawa, D. and Anders, 
H. J. 2016. Matters of life and death. How 
neutrophils die or survive along NET release and 
is “NETosis” = necroptosis? Cell Mol. Life Sci. 73, 
2211–2219.
 82. Zawrotniak, M. and Rapala-Kozik, M. 2013. 
Neutrophil extracellular traps (NETs)—
Formation and implications. Acta Biochim. Pol. 60, 
277–284.
 83. Brinkmann, V., Reichard, U., Goosmann, 
C., Fauler, B., Uhlemann, Y., Weiss, D. S., 
Weinrauch, Y. and Zychlinsky, A. 2004. 
Neutrophil extracellular traps kill bacteria. 
Science 303, 1532–1535.
 84. Czaikoski, P. G., Mota, J. M., Nascimento, D. 
C., Sonego, F., Castanheira, F. V., Melo, P. H., 
Scortegagna, G. T. et al. 2016. Neutrophil extra-
cellular traps induce organ damage during experi-
mental and clinical sepsis. PLOS ONE 11, e0148142.
 85. Camicia, G., Pozner, R. and de Larranaga, G. 
2014. Neutrophil extracellular traps in sepsis. 
Shock 42, 286–294.
 86. Silk, E., Zhao, H., Weng, H. and Ma, D. 2017. The 
role of extracellular histone in organ injury. Cell 
Death Dis. 8, e2812.
 87. Margraf, S., Logters, T., Reipen, J., Altrichter, J., 
Scholz, M. and Windolf, J. 2008. Neutrophil-
derived circulating free DNA (cf-DNA/NETs): A 
potential prognostic marker for posttraumatic 
development of inflammatory second hit and 
sepsis. Shock 30, 352–358.
 88. Mohammed, B. M., Fisher, B. J., Kraskauskas, 
D., Farkas, D., Brophy, D. F., Fowler, A. A. and 
Natarajan, R. 2013. Vitamin C: A novel regulator 
of neutrophil extracellular trap formation. 
Nutrients 5, 3131–3151.
 89. Natarajan, R., Fisher, B. J., Syed, A. A. and Fowler, 
A. A. 2014. Impact of intravenous ascorbic acid 
infusion on novel biomarkers in patients with 
severe sepsis. J. Pulm. Respir. Med. 4, 8p.
 90. Demaret, J., Venet, F., Friggeri, A., Cazalis, 
M. A., Plassais, J., Jallades, L., Malcus, C. et al. 
2015. Marked alterations of neutrophil functions 
during sepsis-induced immunosuppression. J. 
Leukoc. Biol. 98, 1081–1090.
 91. Alves-Filho, J. C., Spiller, F. and Cunha, F. Q. 
2010. Neutrophil paralysis in sepsis. Shock 34 
(Suppl 1), 15–21.
 92. Hotchkiss, R. S., Monneret, G. and Payen, D. 
2013. Sepsis-induced immunosuppression: 
From cellular dysfunctions to immunotherapy. 
Nat. Rev. Immunol. 13, 862–874.
 93. Rebora, A., Crovato, F., Dallegri, F. and Patrone, 
F. 1980. Repeated staphylococcal pyoderma in 
two siblings with defective neutrophil bacterial 
killing. Dermatologica. 160, 106–112.
 94. Patrone, F., Dallegri, F., Bonvini, E., Minervini, 
F. and Sacchetti, C. 1982. Disorders of neutrophil 
function in children with recurrent pyogenic 
infections. Med. Microbiol. Immunol. 171, 113–122.
 95. Boura, P., Tsapas, G., Papadopoulou, A., 
Magoula, I. and Kountouras, G. 1989. Monocyte 
locomotion in anergic chronic brucellosis 
patients: The in vivo effect of ascorbic acid. 
Immunopharmacol. Immunotoxicol. 11, 119–129.
 96. Anderson, R. and Theron, A. 1979. Effects 
of ascorbate on leucocytes: Part III. In vitro 
and in vivo stimulation of abnormal neutro-
phil motility by ascorbate. S. Afr. Med. J. 56, 
429–433.
 97. Corberand, J., Nguyen, F., Fraysse, B. and 
Enjalbert, L. 1982. Malignant external otitis 
and polymorphonuclear leukocyte migration 
impairment. Improvement with ascorbic acid. 
Arch. Otolaryngol. 108, 122–124.
 98. Levy, R. and Schlaeffer, F. 1993. Successful 
treatment of a patient with recurrent 
furunculosis by vitamin C: Improvement of 
clinical course and of impaired neutrophil 
functions. Int. J. Dermatol. 32, 832–834.
 99. Vohra, K., Khan, A. J., Telang, V., Rosenfeld, 
W. and Evans, H. E. 1990. Improvement of 
neutrophil migration by systemic vitamin C in 
neonates. J. Perinatol. 10, 134–136.
 100. Rebora, A., Dallegri, F. and Patrone, F. 1980. 
Neutrophil dysfunction and repeated infections: 
Influence of levamisole and ascorbic acid. Br. J. 
Dermatol. 102, 49–56.
133VItaMIN C IN PNEUMONIa aND SEPSIS
 101. Washko, P., Rotrosen, D. and Levine, M. 
1989. Ascorbic acid transport and accumula-
tion in human neutrophils. J. Biol. Chem. 264, 
18996–19002.
 102. Evans, R. M., Currie, L. and Campbell, A. 1982. 
The distribution of ascorbic acid between 
various cellular components of blood, in normal 
individuals, and its relation to the plasma 
concentration. Br. J. Nutr. 47, 473–482.
 103. Corpe, C. P., Lee, J. H., Kwon, O., Eck, P., 
Narayanan, J., Kirk, K. L. and Levine, M. 2005. 
6-Bromo-6-deoxy-L-ascorbic acid: An ascorbate 
analog specific for Na+-dependent vitamin 
C transporter but not glucose transporter 
pathways. J. Biol. Chem. 280, 5211–5220.
 104. Hume, R. and Weyers, E. 1973. Changes in 
leucocyte ascorbic acid during the common 
cold. Scott. Med. J. 18, 3–7.
 105. Carr, A. and Frei, B. 1999. Does vitamin C act as 
a pro-oxidant under physiological conditions? 
FASEB J. 13, 1007–1024.
 106. Sen, C. K. and Packer, L. 1996. Antioxidant and 
redox regulation of gene transcription. FASEB J. 
10, 709–720.
 107. Macdonald, J., Galley, H. F. and Webster, N. R. 
2003. Oxidative stress and gene expression in 
sepsis. Br. J. Anaesth. 90, 221–232.
 108. Chousterman, B. G., Swirski, F. K. and Weber, 
G. F. 2017. Cytokine storm and sepsis disease 
pathogenesis. Semin. Immunopathol. 39, 517–528.
 109. Wilson, J. X. 2013. Evaluation of vitamin C for 
adjuvant sepsis therapy. Antioxid. Redox Signal. 19, 
2129–2140.
 110. Oudemans-van Straaten, H. M., Spoelstra-de 
Man, A. M. and de Waard, M. C. 2014. Vitamin 
C revisited. Crit. Care 18, 460.
 111. Englard, S. and Seifter, S. 1986. The biochemical 
functions of ascorbic acid. Annu. Rev. Nutr. 6, 
365–406.
 112. Kuiper, C. and Vissers, M. C. 2014. Ascorbate as 
a co-factor for Fe- and 2-oxoglutarate dependent 
dioxygenases: Physiological activity in tumor 
growth and progression. Front. Oncol. 4, 359.
 113. Young, J. I., Zuchner, S. and Wang, G. 2015. 
Regulation of the epigenome by vitamin C. Annu. 
Rev. Nutr. 35, 545–564.
 114. May, J. M. and Harrison, F. E. 2013. Role of 
vitamin C in the function of the vascular 
endothelium. Antioxid. Redox Signal. 19, 
2068–2083.
 115. Rebouche, C. J. 1991. Ascorbic acid and carnitine 
biosynthesis. Am. J. Clin. Nutr. 54, 1147S–1152S.
 116. Brealey, D., Brand, M., Hargreaves, I., Heales, S., 
Land, J., Smolenski, R., Davies, N. A., Cooper, 
C. E. and Singer, M. 2002. Association between 
mitochondrial dysfunction and severity and 
outcome of septic shock. Lancet 360, 219–223.
 117. Moskowitz, A., Andersen, L. W., Huang, D. 
T., Berg, K. M., Grossestreuer, A. V., Marik, P. 
E., Sherwin, R. L. et  al. 2018. Ascorbic acid, 
corticosteroids, and thiamine in sepsis: A review 
of the biologic rationale and the present state of 
clinical evaluation. Crit. Care 22, 283.
 118. De Backer, D. and Scolletta, S. 2013. Clinical 
management of the cardiovascular failure in 
sepsis. Curr. Vasc. Pharmacol. 11, 222–242.
 119. Levine, M. 1986. Ascorbic acid specifically 
enhances dopamine beta-monooxygenase 
activity in resting and stimulated chromaffin 
cells. J. Biol. Chem. 261, 7347–7356.
 120. May, J. M., Qu, Z. C., Nazarewicz, R. and 
Dikalov, S. 2013. Ascorbic acid efficiently 
enhances neuronal synthesis of norepinephrine 
from dopamine. Brain Res. Bull. 90, 35–42.
 121. May, J. M., Qu, Z. C. and Meredith, M. E. 2012. 
Mechanisms of ascorbic acid stimulation of 
norepinephrine synthesis in neuronal cells. 
Biochem. Biophys. Res. Commun. 426, 148–152.
 122. Hornig, D. 1975. Distribution of ascorbic acid, 
metabolites and analogues in man and animals. 
Ann. N. Y. Acad. Sci. 258, 103–118.
 123. Vissers, M. C., Bozonet, S. M., Pearson, J. F. and 
Braithwaite, L. J. 2011. Dietary ascorbate intake 
affects steady state tissue concentrations in 
vitamin C-deficient mice: Tissue deficiency after 
suboptimal intake and superior bioavailability 
from a food source (kiwifruit). Am. J. Clin. Nutr. 
93, 292–301.
 124. Hughes, R. E., Hurley, R. J. and Jones, P. R. 1971. 
The retention of ascorbic acid by guinea-pig 
tissues. Br. J. Nutr. 26, 433–438.
 125. Hasselholt, S., Tveden-Nyborg, P. and Lykkesfeldt, 
J. 2015. Distribution of vitamin C is tissue specific 
with early saturation of the brain and adrenal 
glands following differential oral dose regimens 
in guinea pigs. Br. J. Nutr. 113, 1539–1549.
 126. Nieboer, P., van der Werf, T. S., Beentjes, J. A., 
Tulleken, J. E., Zijlstra, J. G. and Ligtenberg, J. 
J. 2000. Catecholamine dependency in a poly-
trauma patient: Relative adrenal insufficiency? 
Intensive Care Med. 26, 125–127.
 127. Duggan, M., Browne, I. and Flynn, C. 1998. 
Adrenal failure in the critically ill. Br. J. Anaesth. 
81, 468–470.
134 VItaMIN C
 128. Hoehn, S. K. and Kanfer, J. N. 1980. Effects 
of chronic ascorbic acid deficiency on guinea 
pig lysosomal hydrolase activities. J. Nutr. 110, 
2085–2094.
 129. Deana, R., Bharaj, B. S., Verjee, Z. H. and Galzigna, L. 
1975. Changes relevant to catecholamine metabo-
lism in liver and brain of ascorbic acid deficient 
guinea-pigs. Int. J. Vitam. Nutr. Res. 45, 175–182.
 130. Bornstein, S. R., Yoshida-Hiroi, M., Sotiriou, 
S., Levine, M., Hartwig, H. G., Nussbaum, R. 
L. and Eisenhofer, G. 2003. Impaired adrenal 
catecholamine system function in mice with 
deficiency of the ascorbic acid transporter 
(SVCT2). FASEB J. 17, 1928–1930.
 131. Padayatty, S. J., Doppman, J. L., Chang, R., Wang, 
Y., Gill, J., Papanicolaou, D. A. and Levine, M. 
2007. Human adrenal glands secrete vitamin C 
in response to adrenocorticotrophic hormone. 
Am. J. Clin. Nutr. 86, 145–149.
 132. Prigge, S. T., Mains, R. E., Eipper, B. A. and 
Amzel, L. M. 2000. New insights into copper 
monooxygenases and peptide amidation: 
Structure, mechanism and function. Cell. Mol. 
Life Sci. 57, 1236–1259.
 133. Merkler, D. J. 1994. C-terminal amidated 
peptides: Production by the in vitro enzymatic 
amidation of glycine-extended peptides and the 
importance of the amide to bioactivity. Enzyme 
Microb. Technol. 16, 450–456.
 134. Treschan, T. A. and Peters, J. 2006. The vasopres-
sin system: Physiology and clinical strategies. 
Anesthesiology. 105, 599–612; quiz 639-540.
 135. Russell, J. A. 2011. Bench-to-bedside review: 
Vasopressin in the management of septic shock. 
Crit. Care. 15, 226.
 136. Giusti-Paiva, A. and Domingues, V. G. 2010. 
Centrally administered ascorbic acid induces 
antidiuresis, natriuresis and neurohypophyseal 
hormone release in rats. Neuro Endocrinol. Lett. 31, 
87–91.
 137. Landry, D. W., Levin, H. R., Gallant, E. M., 
Ashton, R. C., Jr., Seo, S., D’Alessandro, D., Oz, 
M. C. and Oliver, J. A. 1997. Vasopressin defi-
ciency contributes to the vasodilation of septic 
shock. Circulation 95, 1122–1125.
 138. Sharshar, T., Blanchard, A., Paillard, M., Raphael, 
J. C., Gajdos, P. and Annane, D. 2003. Circulating 
vasopressin levels in septic shock. Crit. Care Med. 
31, 1752–1758.
 139. Sharshar, T., Carlier, R., Blanchard, A., Feydy, 
A., Gray, F., Paillard, M., Raphael, J. C., 
Gajdos, P. and Annane, D. 2002. Depletion of 
neurohypophyseal content of vasopressin in 
septic shock. Crit. Care Med. 30, 497–500.
 140. Kruger, S., Papassotiriou, J., Marre, R., Richter, K., 
Schumann, C., von Baum, H., Morgenthaler, N. G., 
Suttorp, N. and Welte, T. 2007. Pro-atrial natriuretic 
peptide and pro-vasopressin to predict severity and 
prognosis in community-acquired pneumonia: 
Results from the German competence network 
CAPNETZ. Intensive Care Med. 33, 2069–2078.
 141. Guignant, C., Voirin, N., Venet, F., Poitevin, F., 
Malcus, C., Bohe, J., Lepape, A. and Monneret, 
G. 2009. Assessment of pro-vasopressin and 
pro-adrenomedullin as predictors of 28-day 
mortality in septic shock patients. Intensive Care 
Med. 35, 1859–1867.
 142. Becker, K. L., Nylen, E. S., White, J. C., Muller, 
B. and Snider, R. H., Jr. 2004. Procalcitonin 
and the calcitonin gene family of peptides in 
inflammation, infection, and sepsis: A journey 
from calcitonin back to its precursors. J. Clin. 
Endocrinol. Metab. 89, 1512–1525.
 143. Arora, S., Singh, P., Singh, P. M. and Trikha, 
A. 2015. Procalcitonin levels in survivors and 
nonsurvivors of sepsis: Systematic review and 
meta-analysis. Shock 43, 212–221.
 144. Vasu, T. S., Cavallazzi, R., Hirani, A., Kaplan, G., 
Leiby, B. and Marik, P. E. 2012. Norepinephrine 
or dopamine for septic shock: Systematic review 
of randomized clinical trials. J. Intensive Care Med. 
27, 172–178.
 145. Schofield, C. J. and Ratcliffe, P. J. 2004. Oxygen 
sensing by HIF hydroxylases. Nat. Rev. Mol. Cell 
Biol. 5, 343–354.
 146. Hirota, K. and Semenza, G. L. 2005. Regulation 
of hypoxia-inducible factor 1 by prolyl and 
asparaginyl hydroxylases. Biochem. Biophys. Res. 
Commun. 338, 610–616.
 147. Dunham-Snary, K. J., Wu, D., Sykes, E. A., 
Thakrar, A., Parlow, L. R. G., Mewburn, J. D., 
Parlow, J. L. and Archer, S. L. 2017. Hypoxic 
pulmonary vasoconstriction: From molecular 
mechanisms to medicine. Chest 151, 181–192.
 148. Elks, P. M., van Eeden, F. J., Dixon, G., Wang, 
X., Reyes-Aldasoro, C. C., Ingham, P. W., Whyte, 
M. K., Walmsley, S. R. and Renshaw, S. A. 2011. 
Activation of hypoxia-inducible factor-1alpha 
(Hif-1alpha) delays inflammation resolution 
by reducing neutrophil apoptosis and reverse 
migration in a zebrafish inflammation model. 
Blood 118, 712–722.
 149. McInturff, A. M., Cody, M. J., Elliott, E. A., 
Glenn, J. W., Rowley, J. W., Rondina, M. T. and 
135VItaMIN C IN PNEUMONIa aND SEPSIS
Yost, C. C. 2012. Mammalian target of rapamycin 
regulates neutrophil extracellular trap formation 
via induction of hypoxia-inducible factor 1 
alpha. Blood 120, 3118–3125.
 150. Minor, E. A., Court, B. L., Young, J. I. and Wang, 
G. 2013. Ascorbate induces Ten-eleven translo-
cation (Tet) methylcytosine dioxygenase-medi-
ated generation of 5-hydroxymethylcytosine. J. 
Biol. Chem. 288(19), 13669–13674.
 151. Yin, R., Mao, S. Q., Zhao, B., Chong, Z., Yang, 
Y., Zhao, C., Zhang, D. et  al. 2013. Ascorbic 
acid enhances Tet-mediated 5-methylcytosine 
oxidation and promotes DNA demethylation in 
mammals. J. Am. Chem. Soc. 135(28), 10396–10403.
 152. Blaschke, K., Ebata, K. T., Karimi, M. M., Zepeda-
Martinez, J. A., Goyal, P., Mahapatra, S., Tam, 
A. et al. 2013. Vitamin C induces Tet-dependent 
DNA demethylation and a blastocyst-like state in 
ES cells. Nature 500, 222–226.
 153. Song, C. X. and He, C. 2013. Potential functional 
roles of DNA demethylation intermediates. Trends 
Biochem. Sci. 38, 480–484.
 154. Camarena, V. and Wang, G. 2016. The epigenetic 
role of vitamin C in health and disease. Cell Mol. 
Life Sci. 73, 1645–1658.
 155. Klose, R. J., Kallin, E. M. and Zhang, Y. 2006. 
JmjC-domain-containing proteins and histone 
demethylation. Nat. Rev. Genet. 7, 715–727.
 156. Tsukada, Y., Fang, J., Erdjument-Bromage, H., 
Warren, M. E., Borchers, C. H., Tempst, P. and 
Zhang, Y. 2006. Histone demethylation by a 
family of JmjC domain-containing proteins. 
Nature 439, 811–816.
 157. Wang, T., Chen, K., Zeng, X., Yang, J., Wu, 
Y., Shi, X., Qin, B. et  al. 2011. The histone 
demethylases Jhdm1a/1b enhance somatic cell 
reprogramming in a vitamin-C-dependent 
manner. Cell Stem Cell. 9, 575–587.
 158. Ebata, K. T., Mesh, K., Liu, S., Bilenky, M., Fekete, 
A., Acker, M. G., Hirst, M., Garcia, B. A. and 
Ramalho-Santos, M. 2017. Vitamin C induces 
specific demethylation of H3K9me2 in mouse 
embryonic stem cells via Kdm3a/b. Epigenetics 
Chromatin. 10, 36.
 159. Manning, J., Mitchell, B., Appadurai, D. A., 
Shakya, A., Pierce, L. J., Wang, H., Nganga, V. 
et al. 2013. Vitamin C promotes maturation of 
T-cells. Antioxid. Redox Signal. 19, 2054–2067.
 160. Sasidharan Nair, V., Song, M. H. and Oh, K. I. 
2016. Vitamin C facilitates demethylation of the 
Foxp3 enhancer in a Tet-dependent manner. 
J. Immunol. 196, 2119–2131.
 161. Song, M. H., Nair, V. S. and Oh, K. I. 2017. 
Vitamin C enhances the expression of IL17 in a 
Jmjd2-dependent manner. BMB Reports 50, 49–54.
 162. Canali, R., Natarelli, L., Leoni, G., Azzini, 
E., Comitato, R., Sancak, O., Barella, L. and 
Virgili, F. 2014. Vitamin C supplementation 
modulates gene expression in peripheral 
blood mononuclear cells specifically upon an 
inflammatory stimulus: A pilot study in healthy 
subjects. Genes. Nutr. 9, 390.
 163. Hemilä, H. and Chalker, E. 2013. Vitamin C 
for preventing and treating the common cold. 
Cochrane Database Syst. Rev. 1, CD000980.
 164. Carr, A. C. 2018. Can a simple chemical help 
to both prevent and treat sepsis. Crit. Care 
22, 247.
 165. Travica, N., Ried, K., Sali, A., Scholey, A., 
Hudson, I. and Pipingas, A. 2017. Vitamin C 
status and cognitive function: A systematic 
review. Nutrients 9.
 166. Kocot, J., Luchowska-Kocot, D., Kielczykowska, 
M., Musik, I. and Kurzepa, J. 2017. Does 
vitamin C influence neurodegenerative diseases 
and psychiatric disorders? Nutrients 9.
 167. Hooper, M. H., Carr, A. and Marik, P. E. 2019. 
The adrenal-vitamin C axis: From fish to guinea 
pigs and primates. Crit. Care 23, 29.
 168. Carr, A. C., Bozonet, S. M., Pullar, J. M., Simcock, 
J. W. and Vissers, M. C. 2013. Human skeletal 
muscle ascorbate is highly responsive to changes 
in vitamin C intake and plasma concentrations. 
Am. J. Clin. Nutr. 97, 800–807.
 169. Carr, A. C., Vissers, M. C. M. and Cook, J. S. 
2014. The effect of intravenous vitamin C on 
cancer- and chemotherapy-related fatigue and 
quality of life. Front. Oncol. 4, 1–7.
 170. Burns, J. J., Mosbach, E. H. and Schulenberg, 
S. 1954. Ascorbic acid synthesis in normal and 
drug-treated rats, studied with L-ascorbic-1-C14 
acid. J. Biol. Chem. 207, 679–687.
 171. Conney, A. H., Bray, G. A., Evans, C. and Burns, 
J. J. 1961. Metabolic interactions between 
L-ascorbic acid and drugs. Ann. N. Y. Acad. Sci. 92, 
115–127.

